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Background: Tuberculosis (TB) remains a major global health problem. To investigate the genotypes of
Mycobacterium tuberculosis (MTB) and the distribution of Beijing family strains, molecular epidemiology technologies
have been used widely.
Methods: From June 2010 to June 2011, 55M. tuberculosis isolates from patients with pulmonary TB were studied
by Beijing family-specific PCR (detection of the deletion of region of difference 105 [RD105]), and mycobacterial
interspersed repetitive units variable number tandem repeat (MIRU-VNTR) analysis. Twenty-four MIRU-VNTR loci
defined the genotypes and clustering characteristics of the local strains. All strains were subjected to a drug
susceptibility test (DST) by the proportion method on Lowenstein-Jensen (LJ) culture media.
Results: Fifty-five clinical isolates of MTB were collected. Beijing family strains represented 85.5% of the isolates
studied. Using 24 loci MIRU-VNTR typing categorized the strains into eight gene groups, 46 genotypes, and seven
clusters. 83.6% (46/55) of the isolates belonged to the largest gene group. Thirty-six isolates (65.5%) were
susceptible, nineteen (34.5%) were resistant to at least one drug, seven (12.8%) were Multidrug-Resistant
Tuberculosis (MDR TB), and two (3.6%) were extremely drug-resistant tuberculosis (XDR-TB).
Conclusion: The results showed there were obvious polymorphisms of VNTRs of MTB clinical strains. Beijing family
strains of MTB were predominant in the Shihezi region of Xinjiang province. There was no correlation between the
drug-resistance and Beijing family strains of MTB. It is necessary to strengthen the monitoring, treatment, and
management of drug-resistance TB in Shihezi region, Xinjiang.
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Tuberculosis (TB) is an infectious disease caused by the
bacillus Mycobacterium tuberculosis (MTB). TB remains
a major public health threat worldwide. China has occu-
pied second place, behind India, among the top five
high-burden countries for the last decade (http://www.
who.int/tb/en). In 2010, there were 8.8 million (range,
8.5–9.2 million) incident cases of TB, and 1.1 million
(range, 0.9–1.2 million) deaths from TB among HIV-
negative people [1]. Genotyping methods have been
extensively used to analyze the recent transmission dynam-
ics of MTB. Different PCR-based genotyping approaches* Correspondence: yuanli832000@sina.com
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reproduction in any medium, provided the ortargeting the variable number of tandem repeats
(VNTR) have been developed, based on the mycobacter-
ial interspersed repetitive units (MIRU) [2,3], which are
considered a good alternative to the reference method
and have proven to be faster and easier to perform. The
discriminatory power of MIRU-VNTR analysis is related
to the number of loci. MIRU-VNTR genotyping is per-
formed by amplifying a panel of 12, 15, or 24 loci [4].
More recently, a set of 24 MIRU-VNTR loci was
reported to have greater discriminatory power than the
original 12 loci system and may exceed that of restric-
tion fragment length polymorphism (RFLP) when com-
bined with spoligotyping [5,6]. The MIRU-VNTR
method is a reliable and reproducible typing method
with high discriminatory power for studying the MTB
population structure in different countries [7-12].Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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jing, China, is ubiquitously and significantly prevalent in
certain world regions, e.g., East Asia [13]. Members of
the MTB Beijing family are a major concern because of
their high prevalence in tuberculosis patients and their
high rate of multi-drug resistance [14]. Several studies
have observed that the Beijing family MTB strains exhi-
bits important pathogenic features that might be asso-
ciated with drug resistant TB in China [15-17]. As the
prevalence of drug resistant clones of MTB varies from
one area to another, studies of the geographical distribu-
tion of resistant clones are useful for understanding the
epidemiological characteristics of TB. Spoligotyping usu-
ally determines the genotype of a Beijing strain of MTB.
However, this technique requires special equipment and
is time-consuming. A previous study demonstrated a
high the correlation between Spoligotyping and the
RD105 deletion for the identification of the Beijing fam-
ily genotype [17]. The simple and rapid new method, the
RDl05 deletion test, was used to identify the Beijing fam-
ily instead of Spoligotyping [18]. RD105 deletions have
previously been reported to be Beijing family strains-
specific. One large sequence polymorphism, the (LSP)-
RD105 genomic deletion, was observed in all Beijing
family strains and thus serves as a useful marker for the
identification of this family of strains [19]. The RD105
deletion test was performed to identify Beijing family
isolates in different countries [20].
Xinjiang is a province on the Northwestern coast of
China. The incidence of TB in Xinjiang is estimated at
463 cases per 100,000 persons per year. The prevalence
of drug-resistant TB in Xinjiang Province is higher than
the average level in China. Xinjiang is a multiethnic area,
being home to 55 ethnicities. The most numerous are
the Uygur (46.06%), followed by Han (39.33%), and Kaz-
akh (7.08%). In the northern regions of Xinjiang, most of
the population is Han, but in the southern regions,
about 85% of the population is Uygur, and only 8% of
the population is Han. Shihezi region is in northern
Xinjiang and has area of 456.8 square kilometers and a
population of 630,000; 95% of the population is Han. In
2008, the network epidemic of Shihezi reported 991 tu-
berculosis cases and prevalence of 152.15/100,000. TB
ranks as the second statutory infectious disease in Shi-
hezi [21].
The main goal of this study was to genotype MTB
strains circulating in the Shihezi region of Xinjiang Prov-
ince using MIRU-VNTR-24 locus analysis and to under-
stand the genetic diversity of Beijing and non-Beijing
isolates by the RD105 deletion test. We also sought to
the determine drug susceptibility patterns of the MTB
isolates and whether the drug resistance of epidemic TB
are directly related to the spread of Beijing family
strains.Methods
Mycobacterial specimens
This study included M. tuberculosis samples isolated be-
tween June 2010 and June 2011 from Shihezi in Xinjiang
Province. Standard questionnaires were used to collect
classical epidemiology data. Information was obtained
on sex, age, place of birth, recent positive smear test,
previous history of TB, and current address.
Strain isolation and drug susceptibility test
The sputum samples were cultured and isolated on
Lowenstein-Jensen (LJ) culture media. Four first-line
anti-TB drugs (isoniazid [INH], rifampicin [RFP], strepto-
mycin [SM], and ethambutol [EMB]) and seven second-
line anti-TB drugs (ofloxacin [Ofx], Capreomycin [Cm],
Amikacin [Am], Kanamycin [KM], P-aminosalicylicacid
[PAS], Ethionamide [Eto], and Cycloserine [Cs]) were
incorporated into LJ medium, at the following concentra-
tions: INH0, 2 μg/ml; RFP, 40.0 μg/ml; SM, 4.0 μg/ml;
EMB, 2.0 μg/ml; Ofx, 2.0 μg/ml; Cm, 40.0 μg/ml; Km,
30.0 μg/ml; Am, 40.0 μg/ml; PAS, 1.0 μg/ml; Eto,
40.0 μg/ml; and Cs, 40.0 μg/m, and used to detect the
drug-resistance of the MTB by the proportion method.
Strain were scored as resistant to a specific drug, or were
defined as sensitive thief their growth rate was< 1%
compared to the control. Strain isolation, identification,
and drug susceptibility tests (DST) were performed at
the Ministry of Education Key Laboratory of Xinjiang
Endemic and Ethnic Disease.
Genomic DNA extraction and molecular identification of
M. tuberculosis isolates
Mycobacterial genomic DNA was extracted from myco-
bacterial colonies growing on LJ medium. Scraped col-
onies were dissolved in 200-300 μl of distilled water and
inactivated at 85°C for 30 min, before being centrifuged
at 8000 r/min for 5 min. The pellets were resuspended
in 300 μl of TE (pH 8.3), boiled for 30 min, and centri-
fuged at 10,000 r/min for 5 min. Supernatants were col-
lected and stored at −20°C until further use [22].
Molecular identification of the mycobacterial isolates
was performed using PCR amplification of the 16 S
rRNA gene and MTP40 gene [23]. The PCR mixture
consisted of 0.2 μg DNA template, 3 μl buffer, 4 μl
10 mM deoxynucleoside triphosphates, 1 μl of each pri-
mer (10 pmol/μl), and 1 μl DNA Taq polymerase. The
amplification cycle was 5 min at 95°C; followed by 30
cycles of 40 s at 95°C, 50 s at 65°C, and 40 s at 72°C;
with a final 10 min at 72°C. PCR products were analyzed
on a 2% agarose gel against a 100-bp DNA ladder.
Genotyping by MIRU-VNTR PCR
MIRU-VNTR genotyping was performed by amplifying
the 24 MIRU-VNTR loci as described previously in a
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consisted of ten original MIRU-VNTR loci; six loci of
exact tandem repeats (ETRs: ETR-A, -B, -C, -D, -E and
–F), five Mtub loci (Mtub4, 21, 30, 38, and 39), and
three Queen’s University of Belfast (QUBs) loci (QUB-
11b, -26, and 4156c). Primers were as described by Sup-
ply et al. [25]. For each reaction, DNA from M. tubercu-
losis H37Rv was used as a positive control, and sterile
water was used as a negative control. PCR products were
electrophoretically separated on 2% agarose gels, using a
100-bp DNA ladder as size markers. From the gel
images, the corresponding MIRU-VNTR bands were
interpreted as copy numbers based on the reference
table in the Supply 2005 protocol [24]. The copy number
at each locus was calculated using the Quantity 1 gel im-
aging system.
Beijing Family strains analysis
The identification of Beijing Family strains was per-
formed by detecting deletions in region of difference 105
(RD105) by PCR [18]. Each PCR mixture was prepared
in a volume of 15 μl containing 50 ng of DNA, 1U of
Taq polymerase, a 0.2 mM concentration of each deoxy-
nucleoside triphosphate (dNTP), and 0.2 μM (each) pri-
mer. The amplification cycle was 5 min at 94°C;
followed by 30 cycles of 30 s at 94°C, 30 s at 62°C, and
45 s at 72°C; with a final step for 10 min at 72°C. PCR




Ninety sputum specimens from patients with pulmonary
TB were collected from June 2010 to June 2011. All of the
pulmonary TB patients were Han Chinese. Among 90
patients, 30 (33.3%) specimens were either culture nega-
tive or had culture contamination and were excluded. In
addition, another five specimens (5.5%) were excluded
because their cultures were mycobacteria other than TB
(MOTT). Therefore, 55 culture positive specimens were
used for this study.
Of the 55 patients, 20 were new TB cases and 35 were
previously treated patients. The mean age of the patients
was 47.21 yr (± 2.26). There were 38 males (69.1%) and
17 females (30.9%).
MIRU-VNTR genotyping
Fifty-five MTB isolates were genotyped and 46 different
VNTR genotypes were detected. Thirty nine strains
(70.9%) were unique and 16 strains (29.1%) could be
grouped into seven clusters, each including 2–3 strains
(Figure 1). Two main clusters which contained 3 (18.7%)
and 3 (18.7%) strains showed 4 2 4 3 5 2 3 3 2 5 2 6 3 3
3 4 5 4 4 4 3 8 6 2 and 4 2 4 3 5 2 3 3 2 5 1 7 3 3 3 4 54 4 4 3 7 5 2 VNTR profiles, respectively. The isolates
were divided into eight groups based on phylogenetic
clustering and genotypic characteristics. Groups I to VIII
contained 2, 2, 1,1,1,46,1 and 1 isolates, respectively
(Table 1). All the clustered isolates were in group VI. In
this study, H37Rv separated into a group (Figure 1).
Epidemic of Beijing family strains in Shihezi of Xinjiang
Province
During the study period, 55M. tuberculosis isolates were
identified using molecular methods. We used the RD105
deletion test instead of spoligotyping, and found that 47
of the 55 isolates (85.5%) were of the Beijing family
genotype, while eight (24.5%) were non-Beijing family
strains.
Characteristics of the clustered isolates
Among the 47 Beijing family isolates, 45 (95.7%) were in
group VI and the remaining two isolates were in groups
V and VII. This suggested that the Beijing family isolates
distributed mainly in group VI. Sixteen isolates (16/47)
were clusters, and were all Beijing family isolates. In
contrast, none of the eight non-Beijing family isolates
were clustered (Table 2).
Drug susceptibility patterns of the MTB isolates
The 55 MTB strains isolated from the sputum samples
of TB patients were subjected to a drug susceptibility
test. Drug susceptibility with the four first-line anti-
tuberculosis and the seven second-line anti-tuberculosis
drugs was examined to determine the association be-
tween drug resistance patterns and genotype.
Thirty-six isolates (65.5%) were susceptible to all
eleven drugs; 19 (34.5%) were resistant to at least one
drug; seven (12.8%) were MDR-TB strains, which were
resistant to at least INH and RIF, the two most powerful
anti- tuberculosis drugs; two (3.6%) were XDR-TB,
defined as MDR TB with further resistance for any qui-
nolones and to >1 of the three classes of second-line
drugs (Cm, Am, or Km)[26]. We examined the distribu-
tion of drug resistance between Beijing and non-Beijing
strains. Among the seven MDR-TB isolates, five (10.6%,
5/47) isolates were Beijing family strains, and two
(0.25%,2/8) were non-Beijing family strains. The rates of
MDR-TB among Beijing and non-Beijing family strains
were not statistically different (P = 0.386). Among the
Beijing family strains, 36.2% (n = 17) were resistant to
any drug; among the non-Beijing family strains, 2.5%
(n = 2) were resistant to any drug (Table 2).
Of the 55 patients, 20 (36.4%) were new TB cases and
35 (63.6%) were previously treated patients. Among the
four MDR-TB patients, all had been previously treated,
while among the 51 patients with non-MDR-TB, 31
patients (60.8%) had been previously treated. However,
Figure 1 Dendrogram deduced from clustering analysis of 55 isolates. By using the 24 loci MIRU-VNTR typing, the results showed that 55
strains were categorized into 8 gene groups, 46 genotypes and 7 clusters.83.6% (46/55) isolates belonged to the largest gene group.
Table 1 MTB characteristics in the eight subgroups
Isolate characteristic Total no. of isolates No. (%) of isolates by subgroup P value
I (n = 2) II(n = 2) III (n = 1) IV (n = 1) V (n = 1) VI (n-46) VII (n = 1) VIII (n = 1)
Beijing strain 47 0 0 0 0 1 45 1 0 <0.0001
Clustered 16 0 0 0 0 0 16 0 0 0.731
n, number of isolates in the subgroup.
Zhang et al. BMC Research Notes 2012, 5:309 Page 4 of 7
http://www.biomedcentral.com/1756-0500/5/309





No. of isolates P value
Beijing (n = 47)
non-Beijing (n= 8)
Resistance
INH 8 7 1
RFP 5 4 1
SM 12 11 1
EMB 6 6 0
PAS 3 3 0
KM 1 1 0
Eto 2 2 0
Cs 2 2 0
CM 2 1 1
Am 1 1 0
Ofx 4 3 1
Any drug-resistance 19 17 2 0.429*
MDR 7 5 2 0.386*
XDR 2 2 0 1*
Susceptibility 36 30 6 0.429*
Clustered 16 16 0 0.113*
*Value by Fisher’s exact test.
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new cases or previously treated cases, as shown in
Table 3.
Discussion
Recent advances in molecular technology, such as
RD105 deletion and MIRU-VNTR typing, have provided
powerful tools for analyzing MTB genotype and trans-
mission patterns, and should prove invaluable for devel-
oping effective infection-control policies.
The RDl05 deletions, which can identify the Beijing
Family strains, are very valuable molecular markers. In
this study, we found that 85.5% of MTB isolates in the
Shihezi region were Beijing family strains. In the previ-







cases n = 35
P value
Susceptible 36 12 24 0.361*
Any drug-resistance 19 8 11 0.361*
MDR 7 0 7 0.154*
XDR 2 0 2 0.264*
Beijing family 47 16 31 0.216*
Clustered 16 5 11 0.427*
*Value by Fisher’s exact test.different in various regions of China, e.g., 80% to 90% in
Beijing, 67% in Ningxia, 89% in Shanghai, 70% in Zhe-
jiang, 91.5% in Tianjin, 55.3% in Guangxi, 80.4% in
Jiangsu, and 89.5% in Heilongjiang [12]. Thus, the Bei-
jing family strains were prevalent in China. The associ-
ation of drug resistance and the Beijing family strains
has become a research hotspot. However, results
obtained differ. These strains may have a particular pro-
pensity for acquiring drug resistance [27]. In our study,
the statistical analysis showed that there was no differ-
ence between the Beijing and non-Beijing family strains
in terms of their drug resistance patterns, indicating that
the Beijing family was less likely to be associated with
the high prevalence of drug resistance in Shihezi region.
In this study, general resistance to at least one drug
and MDR were all higher than the resistance rate
observed in 2008 [28]. The presence of two XDR-TB
cases (3.6%) was another important discovery, and it is
the first report of XDR-TB cases in Xinjiang. Worldwide,
XDR-TB cases have been reported in 45 countries [29].
In China, a survey of resistance to tuberculosis showed
that the rate of XDR-TB was 0.68% in 2007–2008 [30].
Therefore, we should pay more attention to MDR-TB
and XDR-TB to control tuberculosis.
The MIRU-VNTR method has been used in molecular
epidemiology studies, and it is adequate for tracking re-
cent transmission and distinguishing relapses and rein-
fections [9]. In addition to its high discriminatory power,
MIRU typing is simple to perform, has a high through-
put, and is highly reproducible with a short turnaround
time. MIRU types are represented in digital format;
therefore, results from different laboratories can be eas-
ily compared. In this study, 55 isolates were classified
into 46 types, eight gene groups, and seven clusters by
MIRU-VNTR typing. The eight major gene groups,
combined with flow epidemiological data, did not iden-
tify the means of mutual transmission and direct con-
tact, because we only focused on strains collected in
June 2010 to June 2011. Patients of the experimental in-
vestigation distributed in a different location of the
transmission chain, and were insufficient to reflect the
full spread relationship. At the same time, we were un-
able to collect the strains of previously treated patients;
therefore, the infection pattern may be the recurrence of
endogenous or recent infection. The analysis indicated
that the Beijing family isolates were less likely to be part
of a cluster. Future studies using more isolates are
required to confirm this hypothesis.
Conclusion
This is the first report of the genotypes of MTB isolated
from patients with pulmonary TB in the Shihezi region
of Xinjiang Province, China. We defined 24 MIRU-
VNTR loci for analyzing the strains. The 55 isolates
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http://www.biomedcentral.com/1756-0500/5/309show a high number (16/55) of clusters, and Beijing
family strains (47/55) are prevalent in Shihezi region.
The drug-resistance rate was high; in particular, two
XDR-TB cases were found. It is necessary to strengthen
the monitoring, treatment and management for drug-
resistance TB. There was no correlation between drug-
resistance and the Beijing family genotype.
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